Enzymogen

Company Overview

Snapshot

Founded in April 2015 by Avi Wener and Meir Azulay, Enzymogen operated with 1–10 employees. The company ceased operations in September 2022.

Business overview

Enzymogen developed a technology platform for manufacturing medical-grade cannabinoids using enzymatic processes. The company focused on converting natural resources into commercially viable products, improving efficiency, and maximizing commercially viable byproducts. Its core functions included full-package projects from clone to final enzyme, clone development across various organisms, process development and optimization, fermenter/bioreactor scale-up, establishment of analytical methods, and GMP manufacturing. Enzymogen's product offerings included Taq DNA polymerase and human gastric lipase, serving the Health Tech &.

Company Intelligence Q&A

What is Enzymogen's primary focus?

Enzymogen's primary focus was on developing a technology platform to manufacture medical-grade cannabinoids using enzymatic processes.

When was Enzymogen founded?

Enzymogen was founded in April 2015.

Who are the co-founders of Enzymogen?

The co-founders of Enzymogen are Avi Wener and Meir Azulay.

What products did Enzymogen offer?

Enzymogen's product offerings included Taq DNA polymerase (nonbacterial source), human gastric lipase, phospholipase C and D, and cholesterol esterase YEH1 and TGL1.

What is the current status of Enzymogen?

Enzymogen ceased to operate in September 2022.